Based in Strasbourg, Dreampath Diagnostics enters a new phase of its development. The company specializing in the automation of workflows of anatomopathology laboratories announces growth funding from the American fund Summit Partners. If the amount of the transaction remains confidential, the investment aims to support the international expansion of Dreampath, and expand its range of products.
Founded in 2012, Dreampath has attacked a logistics link still little transformed into the medical diagnostic chain that is Management of fabric samples. At a time when laboratories are facing growth in the volume of analysis, increased traceability requirements and a shortage of personnel, the company offers an integrated platform that combines Scanners, owner and consumable software To automate archiving and recovery of pathological samples.
“”Pathology laboratories are an essential element of the world ecosystem of health care, but many of them still depend on manual processes and subjects to errors for archiving and recovery of samples“, noted Pablo Jordanco -founder and CEO of Dreampath Diagnostics. “”Our mission is to improve the efficiency and precision of these workflows through automation and digital traceability, allowing laboratories to provide patients with faster and safer diagnostics.»»
An integrated platform, thought for industrial use
The solution developed by Dreampath is based on a closed loop systemcovering the entire life cycle of tissue samples in a laboratory. The company claims interoperability with market software infrastructure while retaining strong control over its own technical standards. Dreampath protected its technology by Over 80 international patents.
To date, more than 250 million samples are managed via the platform in 500 laboratories in nearly 40 countriesincluding public hospitals, cancer centers, industrial laboratories and research institutes. The company reports a 83 % reduction in archiving in equipped establishments.
By ensuring rigorous digital traceability, Dreampath contributes to limiting handling errors and securing the diagnostic process, while reducing the operational burden for laboratory teams.
Summit Partners enters the capital and joins governance
With this investment, Dreampath welcomes Summit Partners as the first institutional partner. The fund, active in the health and technology sectors, provides expertise in the scale of high growth companies.
“”Pathology laboratories have to face growing volumes, staff shortages and increasing clarification requests, while working with techniques that have not changed significantly for decades“Comments Thomas TarnowskiManaging Director of Summit Partners. “”The Dreampath platform is designed to remedy a major bottleneck in the workflow in pathology. By allowing rapid and traceable access to fabric samples, the company promotes more coherent laboratory operations and helps improve the quality of care provided to patients. »»
Summit Partners sees in Dreampath an opportunity to structure a Reference industrial player In a still scanned segment of the medical diagnosis. “NWe were seduced by Dreampath because of its clear management in a growing and increasingly important sector of laboratory diagnosis“Addes Jono Pagdendirector at Summit Partners.
The two representatives of Summit, Thomas Tarnowski And Jono Pagdenjoin the board of directors of Dreampath as part of this operation.
A sustained growth trajectory
Dreampath claims a annual growth rate made up of more than 50 % In recent years, brought by demand in the United States, Europe and other strategic markets. Its economic model is based on the combined sale of software, hardware and consumables with high added value, ensuring a recurring income.
The company plans to expand its industrial footprint, increase its production capacity and continue to structure its network of hospital and industrial partners.
